

ICD-10-CM quick reference pocket guide

DUPIXENT[®]
(dupilumab) Injection
100mg • 200mg • 300mg

The coding information in this document is provided for informational purposes only and is subject to change. The codes listed may not apply to all patients or to all health plans; healthcare providers should exercise independent clinical judgment when selecting codes and submitting claims to accurately reflect the services and products furnished to a specific patient.

Importantly, since ICD-10-CM codes do not align with the precise language of the approved indications for DUPIXENT[®] (dupilumab), their inclusion in this document is not meant to suggest that all patients who may be accurately categorized by a given code are necessarily appropriate candidates for DUPIXENT. Similarly, the list is not exhaustive in that there may be patients whose condition is accurately categorized by a particular code that is not listed in this document and who may be appropriate candidates for DUPIXENT.

Use this ICD-10-CM coding guide to assist with:

- Patients aged 6 years and older with uncontrolled moderate-to-severe atopic dermatitis
- Patients aged 6 years and older who require add-on maintenance treatment for moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma
- Patients aged 18 years and older who require add-on maintenance treatment for inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)

INDICATIONS

Atopic Dermatitis: DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

Asthma: DUPIXENT is indicated as an add-on maintenance treatment of patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

Chronic rhinosinusitis with nasal polyposis (CRSwNP): DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled CRSwNP.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

➤ ICD-10-CM codes for moderate-to-severe atopic dermatitis¹

The following diagnostic codes may be submitted to health plans for your patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. If you deem it necessary, you may use as many secondary codes as needed to appropriately describe each patient's condition.

- L20 Atopic dermatitis
- L20.0 Besnier's prurigo
- L20.81 Atopic neurodermatitis
- L20.82 Flexural eczema
- L20.84 Intrinsic (allergic) eczema
- L20.89 Other atopic dermatitis
- L20.9 Atopic dermatitis, unspecified

For more information about the *DUPIXENT MyWay*[®] Patient Support Program, call 1-844-DUPIXENT(T) (1-844-387-4936) Option 1, Monday–Friday, 8 AM–9 PM Eastern time or contact your FRM

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, erythema multiforme, anaphylaxis, and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT with conjunctivitis being the most frequently reported eye disorder in these patients. Conjunctivitis also occurred more frequently in chronic rhinosinusitis with nasal polyposis subjects who received DUPIXENT. Advise patients to report new onset or worsening eye symptoms to their healthcare provider.

Eosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy. These events may be associated with the reduction of oral corticosteroid therapy. Physicians should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. Cases of eosinophilic pneumonia were reported in adult patients who participated in the asthma development program and cases of vasculitis consistent with EGPA have been reported with DUPIXENT in adult patients who participated in the asthma development program as well as in adult patients with co-morbid asthma in the CRSwNP development program. A causal association between DUPIXENT and these conditions has not been established.

Acute Asthma Symptoms or Deteriorating Disease: Do not use DUPIXENT to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of DUPIXENT.

FRM=Field Reimbursement Manager.

➤ ICD-10-CM codes for respiratory indications¹

The following diagnostic codes may be submitted to health plans for your patients:

- aged 6 years and older who require add-on maintenance treatment for moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma

OR

- aged 18 and older who require add-on maintenance treatment for inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)

If you deem it necessary, you may use as many secondary codes as needed to appropriately describe each patient's condition.

Moderate-to-severe asthma

- J45.4 Moderate persistent asthma
- J45.40 Moderate persistent asthma, uncomplicated
- J45.41 Moderate persistent asthma with (acute) exacerbation
- J45.5 Severe persistent asthma
- J45.50 Severe persistent asthma, uncomplicated
- J45.51 Severe persistent asthma with (acute) exacerbation
- J45.9 Other and unspecified asthma
- J45.90 Unspecified asthma
- J45.901 Unspecified asthma with (acute) exacerbation
- J82.83 Eosinophilic asthma

Chronic rhinosinusitis with nasal polyposis

- J33 Nasal polyp
- J33.0 Polyp of the nasal cavity
- J33.1 Polypoid sinus degeneration
- J33.8 Other polyp of sinus
- J33.9 Nasal polyp, unspecified

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

DUPIXENT[®]
(dupilumab) Injection
100mg · 200mg · 300mg

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

Patients with Co-Morbid Asthma: Advise patients with atopic dermatitis or CRSwNP who have co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves. Helminth infections (5 cases of enterobiasis and 1 case of ascariasis) were reported in pediatric patients 6 to 11 years old in the pediatric asthma development program.

ADVERSE REACTIONS:

- **Atopic dermatitis:** The most common adverse reactions (incidence $\geq 1\%$ at Week 16) in adult patients are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.
- **Asthma:** The most common adverse reactions (incidence $\geq 1\%$) are injection site reactions, oropharyngeal pain, and eosinophilia.
- **Chronic rhinosinusitis with nasal polyposis:** The most common adverse reactions (incidence $\geq 1\%$) are injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.

DRUG INTERACTIONS: Avoid use of live vaccines in patients treated with DUPIXENT.

USE IN SPECIFIC POPULATIONS

- **Pregnancy:** A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information, call 1-877-311-8972 or go to <https://mothertobaby.org/ongoing-study/dupixent/>. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
- **Lactation:** There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

For any questions or concerns, or to report side effects with a Sanofi and Regeneron product while enrolled in *DUPIXENT MyWay*[®], please contact 1-844-DUPIXENT(T) (1-844-387-4936) Option 1, Monday–Friday, 8 AM–9 PM Eastern time.

Reference: 1. Centers for Medicare & Medicaid Services. 2022 ICD-10-CM. Updated August 27, 2021. Accessed September 14, 2021. <https://www.cms.gov/medicare/icd-10/2022-icd-10-cm>

SANOI GENZYME  REGENERON

DUPIXENT[®] and *DUPIXENT MyWay*[®] are registered trademarks of Sanofi Biotechnology.
© 2021 Sanofi and Regeneron Pharmaceuticals, Inc.
All Rights Reserved. 10/2021 DUP.21.08.0234

DUPIXENT[®] 
(dupilumab) Injection
100mg • 200mg • 300mg